Could a single pill replace three diabetes drugs? early study begins
NCT ID NCT07548957
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new experimental pill called UI087, which combines three diabetes drugs into one. Researchers want to see if it is safe and how the body processes it compared to taking the three drugs separately. The study involves 44 healthy adults and is not yet testing the drug in people with diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UI087 (a combination pill for type 2 diabetes)
What this could lead to
If successful, this could lead to a simpler, single-pill treatment for type 2 diabetes, replacing the need to take three separate drugs.
What could go wrong
This is a very early (Phase 1) study in healthy volunteers, not people with diabetes. It only checks safety and drug levels, not whether it actually works for diabetes. The results may not translate to patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H plus Yangji Hospital
Seoul, Gwanak-gu, 08779, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••